Rajputana Bio.

Why is Rajputana Biodiesel Ltd falling/rising?

As of 18-Jul, Rajputana Biodiesel Ltd's stock price is Rs. 192.55, down 0.28%, with significant declines over various periods and a new 52-week low of Rs. 180. The stock is underperforming compared to the Sensex and is trading below all key moving averages, indicating a bearish trend despite increased investor participation.

As of 18-Jul, Rajputana Biodiesel Ltd's stock price is falling, currently at Rs. 192.55, reflecting a decrease of Rs. 0.55 or 0.28%. The stock has experienced a significant decline over various periods, with a 1-week drop of 7.41%, a 1-month decline of 11.14%, and a year-to-date decrease of 19.84%. Additionally, the stock has reached a new 52-week low of Rs. 180 today.<BR><BR>The performance of Rajputana Biodiesel Ltd is notably underperforming compared to the Sensex, which has shown positive returns across the same periods. The company's stock is trading below its moving averages for 5 days, 20 days, 50 days, 100 days, and 200 days, indicating a bearish trend. Although there has been a notable increase in investor participation, with delivery volume rising by 275% against the 5-day average, the overall market sentiment remains negative, contributing to the stock's decline.

Which are the latest news on Rajputana Bio.?

What does Rajputana Bio. do?

Rajputana Biodiesel Ltd is a micro-cap company focused on biodiesel production, having transitioned from a private to a public limited company in July 2024. It has a market cap of INR 150 Cr, with key metrics including a P/E ratio of 16.00 and a debt-equity ratio of 0.52.

Overview:<BR>Rajputana Biodiesel Ltd operates in the miscellaneous industry as a micro-cap company focused on biodiesel production.<BR><BR>History:<BR>The company was incorporated on November 10, 2016, originally as Rajputana Biodiesel Systems Private Limited. It transitioned from a Private Limited Company to a Public Limited Company, adopting the name 'Rajputana Biodiesel Limited' with a new Certificate of Incorporation issued on July 8, 2024. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 150 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 16.00<BR>Industry P/E: 42<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.52<BR>Return on Equity: 18.17%<BR>Price-to-Book: 3.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Rajputana Bio.?

Rajputana Bio.'s peers include De Neers Tools, Spacenet Enterprises, Infollion Research, Rockingdeals Cir, Durlax Top, Mitcon Consulting, Crown Lifters, Aesthetik Engineering, and Glittek Granites. Management risk varies from excellent to below average among peers, with Rockingdeals Cir showing the highest 1-year return at 16.14%, while Rajputana Bio. has a return of -14.15%.

Peers: The peers of Rajputana Bio. are De Neers Tools, Spacenet Enterpr, Infollion Resea., Rockingdeals Cir, Durlax Top, Mitcon Consult., Crown Lifters, Aesthetik Engi., and Glittek Granites.<BR><BR>Quality Snapshot: Excellent management risk is observed at De Neers Tools, Infollion Resea., and Rockingdeals Cir, while Good management risk is found at Rajputana Bio., Crown Lifters, and Aesthetik Engi. Average management risk is noted at Durlax Top and Glittek Granites, while Below Average management risk is seen at Spacenet Enterpr and Mitcon Consult. Growth is Excellent at Rockingdeals Cir and Aesthetik Engi., Good at De Neers Tools, Infollion Resea., Rajputana Bio., and Crown Lifters, while Average growth is found at Durlax Top and Glittek Granites, and Below Average growth is noted at Spacenet Enterpr and Mitcon Consult. Capital Structure is Excellent at Spacenet Enterpr and Infollion Resea., Good at De Neers Tools, Rajputana Bio., Crown Lifters, and Aesthetik Engi., Average at Durlax Top and Glittek Granites, and Below Average at Mitcon Consult.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Rockingdeals Cir at 16.14%, while the lowest is Infollion Resea. at -64.71%. Rajputana Bio.'s 1-year return of -14.15% is better than Infollion Resea. but worse than Rockingdeals Cir. Additionally, Spacenet Enterpr, Infollion Resea., Mitcon Consult., Crown Lifters, Aesthetik Engi., and Glittek Granites all have negative six-month returns.

How has been the historical performance of Rajputana Bio.?

Rajputana Bio's historical performance shows growth in net sales and profits, with net sales increasing to 67.31 crore and profit after tax rising to 5.92 crore for the fiscal year ending March 2025. However, cash flow from operating activities was negative at -15.00 crore, indicating challenges in cash flow management.

Answer:<BR>The historical performance of Rajputana Bio shows a positive trend in key financial metrics over the past year.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Rajputana Bio reported net sales of 67.31 crore, an increase from 53.46 crore in March 2024. The total operating income also rose to 67.31 crore from 53.46 crore, while total expenditure increased to 58.37 crore from 45.75 crore. This resulted in an operating profit (PBDIT) of 10.23 crore, up from 7.93 crore the previous year. Profit before tax improved to 7.53 crore from 6.14 crore, leading to a profit after tax of 5.92 crore, compared to 4.56 crore in the prior year. The company’s earnings per share slightly decreased to 8.42 from 8.89, while the PAT margin improved to 8.8% from 8.53%. On the balance sheet, total assets grew to 60.49 crore from 42.30 crore, with total liabilities also increasing to 60.49 crore from 42.30 crore. Cash flow from operating activities showed a negative trend at -15.00 crore, though financing activities provided a net inflow of 15.00 crore. Overall, Rajputana Bio's financial performance indicates growth in sales and profits, despite challenges in cash flow management.

Is Rajputana Bio. overvalued or undervalued?

As of August 28, 2025, Rajputana Bio. is considered very expensive and overvalued with a high PE ratio of 30.61, a Price to Book Value of 12.86, and an EV to EBITDA of 22.18, despite a recent 16.38% return, it has underperformed year-to-date with a 16.97% decline compared to the Sensex's 3.62% gain.

As of 28 August 2025, Rajputana Bio. has moved from a fair valuation to very expensive. The company is currently overvalued, as indicated by its high PE ratio of 30.61, a Price to Book Value of 12.86, and an EV to EBITDA of 22.18. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Rajputana Bio.'s PE ratio is significantly lower than Solar Industries, which has a PE of 99.06, but higher than Godrej Industries, which stands at 41.86. Additionally, the PEG ratio of Rajputana Bio. is 0.00, indicating no growth relative to its price, which further supports the conclusion of overvaluation. Notably, while Rajputana Bio. has experienced a 16.38% return over the past month, it has underperformed on a year-to-date basis, down 16.97%, contrasting with the Sensex's 3.62% gain.

How big is Rajputana Bio.?

As of 24th July, Rajputana Biodiesel Ltd has a market capitalization of 156.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 14.22 Cr and Total Assets of 42.30 Cr; however, there is no valid financial data available for net sales or net profit for the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Rajputana Biodiesel Ltd has a market capitalization of 156.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 14.22 Cr and Total Assets valued at 42.30 Cr.

What is the technical trend for Rajputana Bio.?

As of June 2, 2025, Rajputana Bio's technical trend is neutral, showing a shift from mildly bearish to sideways, with no clear signals from key indicators like MACD, KST, and RSI.

As of 2 June 2025, the technical trend for Rajputana Bio has changed from mildly bearish to sideways. The weekly MACD and KST show no clear signals, while the monthly indicators are also lacking definitive trends. The RSI on the weekly timeframe indicates no signal, and the Dow Theory suggests a mildly bearish stance on the weekly chart. The Bollinger Bands are indicating a sideways movement on both weekly and monthly timeframes. Overall, the current technical stance is neutral, reflecting a lack of strong directional momentum.

Who are the top shareholders of the Rajputana Bio.?

The top shareholders of Rajputana Bio include promoter Sudeep Soni with 22.45%, followed by Nine Alps Trust-nine Alps Opportunity Fund at 3.38%, and individual investors holding 24.83%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Rajputana Bio include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sudeep Soni, who owns 22.45% of the company. In terms of public shareholders, the highest is Nine Alps Trust-nine Alps Opportunity Fund, with a holding of 3.38%. Additionally, individual investors collectively hold 24.83% of the shares. There are also two foreign institutional investors (FIIs) that hold a combined 0.48% of the company. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

When is the next results date for Rajputana Bio.?

No Upcoming Board Meetings

Has Rajputana Bio. declared dividend?

No Dividend History Available